Vuity eye drop available for presbyopia treatment
Click Here to Manage Email Alerts
Vuity, an eye drop for the treatment of presbyopia, is now available, according to a press release from AbbVie.
“We are pleased to be able to bring this first-of-its-kind treatment to market sooner than expected for the millions of Americans with presbyopia who may benefit from it,” Jag Dosanjh, senior vice president medical therapeutics at Allergan, an AbbVie company, said in the release.
Vuity delivers a formulation of pilocarpine to the eye to reduce pupil size, improving near and intermediate vision without sacrificing distance vision.
The FDA approved Vuity in October following positive results from the pivotal phase 3 GEMINI 1 and GEMINI 2 clinical studies that assessed the efficacy, safety and tolerability of Vuity for presbyopia. Both studies met their primary endpoints with a significant proportion of patients treated with Vuity gaining three lines or more in mesopic, high-contrast, binocular distance corrected near visual acuity without losing more than one line of corrected distance visual acuity at day 30, hour 3, compared with placebo.
The once-daily treatment is the first eye drop approved by the FDA for presbyopia.
Read more about
Click Here to Manage Email Alerts